Phase I dose-escalation study of oral administration of MET Tyrosine Kinase Inhibitor S 49076 in patients with advanced solid tumours

Trial Profile

Phase I dose-escalation study of oral administration of MET Tyrosine Kinase Inhibitor S 49076 in patients with advanced solid tumours

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Sep 2015

At a glance

  • Drugs S-49076 (Primary)
  • Indications Colorectal cancer; Non-small cell lung cancer; Solid tumours; Uveal melanoma
  • Focus Adverse reactions
  • Sponsors Servier
  • Most Recent Events

    • 01 Nov 2013 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
    • 23 Oct 2013 Interim results presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
    • 08 Aug 2013 Planned end date changed from 15 Sep 2015 to 15 Sep 2014 as reported by ISRCTN: Current Controlled Trials record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top